Monday, September 7, 2015

Green tea components may help prevent prostate cancer development in at-risk men

›
In continuation from my update on epigallocatechin Prostate cancer is the second most common type of cancer in men and is predicted ...
Friday, September 4, 2015

Existing anti-stroke drug can be effective in treating middle-ear infections

›
In continuation of my update on  Vinpocetine An existing anti-stroke drug is an effective treatment for middle-ear infections, showing...
Thursday, September 3, 2015

Brigatinib drug shows promise against ALK non-small cell lung cancer in phase I/II clinical trial

›
Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising r...
Wednesday, September 2, 2015

Scorpion venom has toxic effects against cancer cells

›
When the toxin invades channels in the cells with this disease produces cellular damage until killing them. In the venom from the Cent...
Tuesday, September 1, 2015

This Little Known Chinese Herb Kills 12,000 Cancer Cells For Every Healthy Cell | Collective-Evolution

›
A little known Chinese herb might be eligible for the growing list of cancer killers via alternative methods of treatment. According to...
Monday, August 31, 2015

Chemical compound shows promise in treating rheumatoid arthritis

›
Montana State University researchers and their collaborators have published their findings about a chemical compound that shows ...
Friday, August 28, 2015

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

›
In continuation of my update on xifaxan Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that its wholl...
Thursday, August 27, 2015

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

›
In continuation of my update on  VIBERZI (eluxadoline) Actavis plc,  announced today that VIBERZI™ (eluxadoline) was approved by the F...
Tuesday, August 25, 2015

First-line axitinib ‘feasible’ in advanced, metastatic RCC

›
We know that, Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has bee...
Monday, August 24, 2015

Drug combination lengthens lives of metastatic colorectal cancer patients

›
                         fluoropyrimidine                    TAS-102  Capecitabine A drug developed 50 years ago and abandon...
Friday, August 21, 2015

Mifepristone-eribulin combination clinically active in triple-negative breast cancer patients

›
Corcept Therapeutics Incorporated, a pharmaceutical company engaged in the discovery, development and commercialization of drugs that trea...
Thursday, August 20, 2015

Drug combination lengthens lives of metastatic colorectal cancer patients

›
                         fluoropyrimidine                    TAS-102  Capecitabine A drug developed 50 years ago and abandon...
Wednesday, August 19, 2015

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

›
The combination of a cholesterol-lowering drug, Bezafibrate (first left structure), and a contraceptive steroid, Medroxyprogesterone Aceta...
Tuesday, August 18, 2015

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

›
An early phase study testing an anti-PDL1 agent in combination with standard chemotherapy in the treatment of advanced non-small cell lung...
Monday, August 17, 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

›
In continuation of my update on  AKYNZEO ® Australian biopharmaceutical company Specialised Therapeutics Australia (STA) and Helsinn, ...